

## A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens

Aaron Y. Chang, ... , Cheng Liu, David A. Scheinberg

*J Clin Invest.* 2017;127(9):3557-3557. <https://doi.org/10.1172/JCI96860>.

### Corrigendum

Original citation: *J Clin Invest.* 2017;127(7):2705–2718. <https://doi.org/10.1172/JCI92335> Citation for this corrigendum: *J Clin Invest.* 2017;127(9):3557. <https://doi.org/10.1172/JCI96860> The last two sentences in the first paragraph of the Discussion section were incorrect. The correct sentences are below. Recently described “ImmTAC” molecules use a TCR-based recognition domain offering similar reactivity to TCRm Abs and demonstrate high affinity (42). Also, TCRm Abs such as Pr20 can target these “undruggable” proteins with high affinity for redirected immune-mediated cytotoxicity. The authors regret the error.

**Find the latest version:**

<https://jci.me/96860/pdf>



## Corrigendum

### The *U2AF1*<sup>S34F</sup> mutation induces lineage-specific splicing alterations in myelodysplastic syndromes

Bon Ham Yip, Violetta Steeples, Emmanouela Repapi, Richard N. Armstrong, Miriam Llorian, Swagata Roy, Jacqueline Shaw, Hamid Dolatshad, Stephen Taylor, Amit Verma, Matthias Bartenstein, Paresh Vyas, Nicholas C.P. Cross, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Christopher W.J. Smith, Andrea Pellagatti, and Jacqueline Boulwood


Original citation: *J Clin Invest*. 2017;127(6):2206–2221. <https://doi.org/10.1172/JCI91363>.

Citation for this corrigendum: *J Clin Invest*. 2017;127(9):3557. <https://doi.org/10.1172/JCI96202>.

In Figure 4D, the horizontal axes of the two graphs were labeled incorrectly, and one sentence in the legend for this part was also incorrect. The correct figure part and sentence are below.

Expression of *H2AFY* isoform 1.1 and the *STRAP* long isoform in *U2AF1*<sup>S34F</sup> and *U2AF1*<sup>WT</sup> transduced cells was measured by isoform-specific qRT-PCR relative to the EV control (red bars: erythroid cells; blue bars: granulomonocytic cells).

The authors regret the error.



## Corrigendum

### A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens

Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa D. Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Cheng Liu, and David A. Scheinberg

Original citation: *J Clin Invest*. 2017;127(7):2705–2718. <https://doi.org/10.1172/JCI92335>.

Citation for this corrigendum: *J Clin Invest*. 2017;127(9):3557. <https://doi.org/10.1172/JCI96860>.

The last two sentences in the first paragraph of the Discussion section were incorrect. The correct sentences are below.

Recently described “ImmTAC” molecules use a TCR-based recognition domain offering similar reactivity to TCRm Abs and demonstrate high affinity (42). Also, TCRm Abs such as Pr20 can target these “undruggable” proteins with high affinity for redirected immune-mediated cytotoxicity.

The authors regret the error.